Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KLKB1 | P03952 | 4/20 | 0.36 |
| ▸ | MET | P08581 | 6/20 | 0.36 |
| ▸ | PARP1 | P09874 | 1/20 | 0.35 |
| ▸ | AR | P10275 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.34 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.33 |
| ▸ | MGLL | Q99685 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13465739 | 0.89 | KDM4E (0.38) | METPARP1LMNAKDM4EMAPT | |
| SCHEMBL13275332 | 0.88 | KDM4E (0.39) | METPARP1LMNAKDM4EMAPT | |
| SCHEMBL13465659 | 0.87 | HPGD (0.41) | METPARP1LMNAKDM4EMAPT | |
| SCHEMBL2221173 | 0.86 | MET (0.40) | METPARP1 | |
| SCHEMBL13449331 | 0.85 | PARP1 (0.49) | METPARP1LMNAKDM4EMAPT | |
| SCHEMBL13275070 | 0.85 | PARP1 (0.39) | METPARP1KDM4EMAPT | |
| SCHEMBL255591 | 0.83 | RORC (0.40) | PARP1LMNAKDM4EMAPT | |
| SCHEMBL2268211 | 0.83 | CHRM4 (0.43) | KLKB1METCHRM4 | |
| SCHEMBL13274789 | 0.82 | MET (0.45) | METLMNAMAPTCHRM4 | |
| SCHEMBL13275144 | 0.82 | ALDH1A1 (0.38) | METPARP1LMNAKDM4EMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120264735-A1 | TYROSINE KINASE INHIBITORS | MERCK SHARP & DOHME CORP. | 2012-10-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120264735-A1 | TYROSINE KINASE INHIBITORS | ABL1, MET, ERBB2 | KLKB1 2827/4885MET 2/4885PARP1 2307/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.